Cover Image
市場調查報告書

多發性骨髓瘤

Multiple Myeloma Disease Coverage Forecast and Market Analysis to 2024

出版商 Datamonitor Healthcare 商品編碼 365183
出版日期 內容資訊 英文 488 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
多發性骨髓瘤 Multiple Myeloma Disease Coverage Forecast and Market Analysis to 2024
出版日期: 2017年10月26日 內容資訊: 英文 488 Pages
簡介

本報告提供多發性骨髓瘤的已上市及臨床實驗中 (開發平台上)的治療藥相關分析,各產品的市場規模的估計值,患病人數的增加要素,及目前代表性產品,開發中產品的上市給予市場的影響,主要產品 (Revlimid、Velcade)的一般化帶給今後的市場規模的影響,美國、日本、歐洲的代表性產品,殘留的未滿足需求等相關調查。

市場預測:多發性骨髓瘤

  • 摘要整理
  • 市場概要與趨勢
  • 市場定義和分析方法
  • Darzalex (Daratumumab)
  • Empliciti (Elotuzumab)
  • Farydak (Panobinostat)
  • Keytruda (pembrolizumab)
  • Kyprolis (carfilzomib)
  • Ninlaro (ixazomib)
  • Pomalyst (pomalidomide)
  • Revlimid (lenalidomide)
  • Selinexor
  • Thalomid (thalidomide)
  • Velcade (bortezomib)
  • 一次調查技術

治療方法:多發性骨髓瘤

  • 摘要整理
  • 一次調查技術
  • 疾病定義與診斷方法
  • 患者的分類
  • 各國治療系統
  • 目前治療選擇
  • 處方的趨勢

流行病學:多發性骨髓瘤

  • 摘要整理
  • 疾病的背景情況
  • 資訊來源、分析方法
  • 流行病學者的見解
  • 分析的優勢與限制

已上市藥物:多發性骨髓瘤

  • 摘要整理
  • 產品概要
  • 產品簡介:Darzalex
  • 產品簡介:Empliciti
  • 產品簡介:Farydak
  • 產品簡介:Kyprolis
  • 產品簡介:Ninlaro
  • 產品簡介:Pomalyst
  • 產品簡介:Revlimid
  • 產品簡介:Thalomid
  • 產品簡介:Velcade

開發中產品:多發性骨髓瘤

  • 摘要整理
  • 臨床實驗開發平台概要
  • 目標產品簡介
  • 臨床實驗的設計
  • 最近,臨床實驗中止的藥物
  • 產品簡介 (最後階段):Aplidin
  • 產品簡介 (最後階段):Keytruda
  • 產品簡介 (最後階段):selinexor

附錄

  • 附錄:多發性骨髓瘤的流行病學

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC5921

DISEASE OVERVIEW:

Multiple myeloma is characterized by the infiltration of malignant, antibody-producing plasma cells in the bone marrow. Almost all cases occur in individuals aged over 40 years, and age at diagnosis has an impact on patient outcome, especially in terms of the treatment options available. Most patients will receive at least three lines of treatment, and eligible patients will receive stem cell transplantation.

MARKET SNAPSHOT:

  • Modest market growth will be driven by label expansions and new launches, but will be moderated by genericization of Revlimid and Velcade.
  • Velcade and Revlimid dominate early treatment settings, but are replaced by newer drugs as patients relapse and become refractory to treatment.
  • The incident population is forecast to undergo a substantial 41% increase from 56,770 cases in 2016 to 80,290 in 2036. The approvals of Empliciti and Darzalex could dramatically change the treatment of MM, as they represent much-needed new treatment options for relapsed MM patients.
  • Keytruda has an extensive development program and promising early-phase data in multiple myeloma.
  • Multiple myeloma drugs will enjoy reimbursement by US payers for the foreseeable future, while novel combinations will spur risk sharing in Europe.

TABLE OF CONTENTS

FORECAST: MULTIPLE MYELOMA

  • Executive Summary
  • Market Overview and Trends
  • Market Definition and Methodology
  • Darzalex (daratumumab)
  • Empliciti (elotuzumab)
  • Farydak (panobinostat)
  • Keytruda (pembrolizumab)
  • Kyprolis (carfilzomib)
  • Ninlaro (ixazomib)
  • Pomalyst (pomalidomide)
  • Revlimid (lenalidomide)
  • selinexor
  • Thalomid (thalidomide)
  • Velcade (bortezomib)
  • Primary Research Methodology

TREATMENT: MULTIPLE MYELOMA

  • Executive Summary
  • Primary Research Methodology
  • Disease Definition and Diagnosis
  • Patient Segmentation
  • Country Treatment Trees
  • Current Treatment Options
  • Prescribing Trends

EPIDEMIOLOGY: MULTIPLE MYELOMA

  • Executive Summary
  • Disease Background
  • Sources and Methodology
  • Forecast
  • Epidemiologist Insight
  • Strengths and Limitations
  • Bibliography
  • Appendix: Additional Sources

MARKETED DRUGS: MULTIPLE MYELOMA

  • Executive Summary
  • Product Overview
  • Product profile: Darzalex
  • Product profile: Empliciti
  • Product profile: Farydak
  • Product profile: Kyprolis
  • Product profile: Ninlaro
  • Product profile: Pomalyst
  • Product profile: Revlimid
  • Product profile: Thalomid
  • Product profile: Velcade

MULTIPLE MYELOMA PRICING, REIMBURSEMENT, AND ACCESS

  • Executive Summary
  • Market Context
  • Global Payer and Key Opinion Leader Insights
  • US Pricing
  • US Payer and Key Opinion Leader Insights
  • US Reimbursement
  • Japan
  • Pricing in the Five Major EU Markets
  • Five Major EU Markets Payer and Key Opinion Leader Insights
  • France
  • Germany
  • Italy
  • Spain
  • UK
  • Appendix

PIPELINE: MULTIPLE MYELOMA

  • Executive Summary
  • Clinical Pipeline Overview
  • Target Product Profile
  • Clinical Trial Design
  • Recently Discontinued Drugs
  • Product profile (late stage): Aplidin
  • Product profile (late stage): Keytruda
  • Product profile (late stage): selinexor

LIST OF FIGURES

  • Figure 1: Multiple myeloma market value across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 2: Multiple myeloma market value in the US, 2015-24
  • Figure 3: Multiple myeloma market value in the five major EU markets, 2015-24
  • Figure 4: Multiple myeloma market value in Japan, 2015-24
  • Figure 5: Combined sales of Darzalex, Empliciti, and Ninlaro in the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 6: Sales of the major multiple myeloma drugs in the US, Japan, and five major EU markets, 2015-24
  • Figure 7: Sales of Kyprolis and Ninlaro in the US, Japan, and five major EU markets, 2015-24
  • Figure 8: Sales of Pomalyst and Revlimid in the US, Japan, and five major EU markets, 2015-24
  • Figure 9: Sales of Empliciti and Darzalex in the US, Japan, and five major EU markets, 2015-24
  • Figure 10: Patient-based forecast methodology for multiple myeloma
  • Figure 11: Price sources and calculations, by country
  • Figure 12: Darzalex sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 13: Empliciti sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 14: Farydak sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 15: Keytruda sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 16: Kyprolis sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 17: Ninlaro sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 18: Pomalyst sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 19: Revlimid sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 20: Selinexor sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 21: Thalomid sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 22: Velcade sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 23: Patients diagnosed with symptomatic and asymptomatic multiple myeloma, by country (%)
  • Figure 24: Primary treatment options for smoldering multiple myeloma patients, by country
  • Figure 25: Top three regimens used for first-line treatment of SCT-eligible multiple myeloma patients, by country
  • Figure 26: Top three drugs used for first-line treatment of SCT-eligible multiple myeloma patients, by country
  • Figure 27: Type of SCT used following first-line therapy in SCT-eligible multiple myeloma patients, by country
  • Figure 28: Proportion of SCT-eligible multiple myeloma patients receiving a second transplant, by country
  • Figure 29: Proportion of SCT-eligible multiple myeloma patients receiving an autologous or allogenic SCT as a second transplant, by country
  • Figure 30: Treatment approach for multiple myeloma patients following SCT, by country
  • Figure 31: Top three regimens used for maintenance therapy after SCT, by country
  • Figure 32: Top three regimens used for second-line treatment of SCT-eligible multiple myeloma patients, by country
  • Figure 33: Top three regimens used for third-line treatment of SCT-eligible multiple myeloma patients, by country
  • Figure 34: Top three regimens used in fourth-line therapy and beyond for SCT-eligible multiple myeloma patients, by country
  • Figure 35: Top three regimens used as first-line treatment of multiple myeloma patients not eligible for SCT, by country
  • Figure 36: Proportion of multiple myeloma patients not eligible for SCT receiving each treatment type after induction therapy, by country
  • Figure 37: Top three regimens used for maintenance after induction therapy in multiple myeloma patients not eligible for SCT, by country
  • Figure 38: Top three regimens used for second-line treatment of multiple myeloma patients not eligible for SCT, by country
  • Figure 39: Top three regimens used for third-line treatment of multiple myeloma patients not eligible for SCT, by country
  • Figure 40: Top three regimens used in fourth-line therapy and beyond for multiple myeloma patients not eligible for SCT, by country
  • Figure 41: Trends in incident cases of multiple myeloma in the US, Japan, and five major EU markets, 2016-36
  • Figure 42: Absolute change in incident cases of multiple myeloma in the US, Japan, and five major EU markets, 2016-36
  • Figure 43: Darzalex for multiple myeloma - SWOT analysis
  • Figure 44: Datamonitor Healthcare's drug assessment summary of Darzalex in multiple myeloma
  • Figure 45: Datamonitor Healthcare's drug assessment summary of Darzalex in multiple myeloma
  • Figure 46: Empliciti for multiple myeloma - SWOT analysis
  • Figure 47: Datamonitor Healthcare's drug assessment summary of Empliciti in multiple myeloma
  • Figure 48: Datamonitor Healthcare's drug assessment summary of Empliciti in multiple myeloma
  • Figure 49: Farydak for multiple myeloma - SWOT analysis
  • Figure 50: Datamonitor Healthcare's drug assessment summary of Farydak in multiple myeloma
  • Figure 51: Datamonitor Healthcare's drug assessment summary of Farydak in multiple myeloma
  • Figure 52: Kyprolis for multiple myeloma - SWOT analysis
  • Figure 53: Datamonitor Healthcare's drug assessment summary of Kyprolis in multiple myeloma
  • Figure 54: Datamonitor Healthcare's drug assessment summary of Kyprolis in multiple myeloma
  • Figure 55: Ninlaro for multiple myeloma - SWOT analysis
  • Figure 56: Datamonitor Healthcare's drug assessment summary of Ninlaro in multiple myeloma
  • Figure 57: Datamonitor Healthcare's drug assessment summary of Ninlaro in multiple myeloma
  • Figure 58: Pomalyst for multiple myeloma - SWOT analysis
  • Figure 59: Datamonitor Healthcare's drug assessment summary of Pomalyst in multiple myeloma
  • Figure 60: Datamonitor Healthcare's drug assessment summary of Pomalyst in multiple myeloma
  • Figure 61: Revlimid for multiple myeloma - SWOT analysis
  • Figure 62: Datamonitor Healthcare's drug assessment summary of Revlimid in multiple myeloma
  • Figure 63: Datamonitor Healthcare's drug assessment summary of Revlimid in multiple myeloma
  • Figure 64: Thalomid for multiple myeloma - SWOT analysis
  • Figure 65: Datamonitor Healthcare's drug assessment summary of Thalomid in multiple myeloma
  • Figure 66: Datamonitor Healthcare's drug assessment summary of Thalomid in multiple myeloma
  • Figure 67: Overview of induction therapy meta-analysis for Velcade in multiple myeloma
  • Figure 68: Velcade for multiple myeloma - SWOT analysis
  • Figure 69: Datamonitor Healthcare's drug assessment summary of Velcade in multiple myeloma
  • Figure 70: Datamonitor Healthcare's drug assessment summary of Velcade in multiple myeloma
  • Figure 71: Clinical benefit of Empliciti, Kyprolis, and Ninlaro when added to a Revlimid and dexamethasone regimen in patients who received 1-3 prior lines of therapy
  • Figure 72: Aplidin for multiple myeloma - SWOT analysis
  • Figure 73: Datamonitor Healthcare's drug assessment summary of Aplidin in multiple myeloma
  • Figure 74: Datamonitor Healthcare's drug assessment summary of Aplidin in multiple myeloma
  • Figure 75: Keytruda for multiple myeloma - SWOT analysis
  • Figure 76: Datamonitor Healthcare's drug assessment summary of Keytruda in multiple myeloma
  • Figure 77: Datamonitor Healthcare's drug assessment summary of Keytruda in multiple myeloma
  • Figure 78: Selinexor for multiple myeloma - SWOT analysis
  • Figure 79: Datamonitor Healthcare's drug assessment summary of selinexor in multiple myeloma
  • Figure 80: Datamonitor Healthcare's drug assessment summary of selinexor in multiple myeloma

LIST OF TABLES

  • Table 1: Multiple myeloma market value across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 2: Multiple myeloma market value in the US ($m), 2015-24
  • Table 3: Multiple myeloma market value in the five major EU markets, by country ($m), 2015-24
  • Table 4: Multiple myeloma market value in Japan ($m), 2015-24
  • Table 5: Combined sales of Darzalex, Empliciti, and Ninlaro in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 6: Sales of the major multiple myeloma drugs in the US, Japan, and five major EU markets ($m), 2015-24
  • Table 7: Sales of Kyprolis and Ninlaro in the US, Japan, and five major EU markets ($m), 2015-24
  • Table 8: Sales of Pomalyst and Revlimid in the US, Japan, and five major EU markets ($m), 2015-24
  • Table 9: Sales of Empliciti and Darzalex in the US, Japan, and five major EU markets ($m), 2015-24
  • Table 10: Sales of Keytruda in the US, Japan, and five major EU markets ($m), by country, 2015-24
  • Table 11: Summary of drug classes and molecules in Datamonitor Healthcare's multiple myeloma patient-based forecast
  • Table 12: Exchange rates used for calculating prices
  • Table 13: Patent expiry dates for key marketed brands in multiple myeloma in the US, Japan, and five major EU markets, by region, 2015-24
  • Table 14: Estimated approval dates for key late-stage pipeline products in multiple myeloma in the US, Japan, and five major EU markets, by region, 2015-24
  • Table 15: Darzalex sales for multiple myeloma across the US, Japan, and five major EU markets ($m), by country, 2015-24
  • Table 16: Empliciti sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 17: Farydak sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 18: Keytruda sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 19: Kyprolis sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 20: Ninlaro sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 21: Pomalyst sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 22: Revlimid sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 23: Selinexor sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 24: Thalomid sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 25: Velcade sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 26: Medical oncologists and hematologists surveyed for the multiple myeloma primary research study, 2015
  • Table 27: Medical oncologists and hematologists surveyed for the multiple myeloma primary research study, 2015
  • Table 28: Disease classification of MGUS and SMM
  • Table 29: Molecular subtypes of multiple myeloma
  • Table 30: Common symptoms of multiple myeloma
  • Table 31: Co-morbidities associated with multiple myeloma
  • Table 32: The International Staging System for multiple myeloma
  • Table 33: The Durie-Salmon staging system for multiple myeloma
  • Table 34: The revised International Staging System criteria for multiple myeloma
  • Table 35: Treatments available for multiple myeloma across the US, Japan, and five major EU markets
  • Table 36: Progression from SMM to active MM across the US, Japan, and five major EU markets, 2015
  • Table 37: Revlimid- and Velcade-containing regimens in first-line therapy for patients eligible for SCT, by country
  • Table 38: Number of additional therapy lines after fifth-line treatment of SCT-eligible multiple myeloma patients, by country
  • Table 39: Number of additional therapy lines after fifth-line treatment of multiple myeloma patients not eligible for an SCT, by country
  • Table 40: Durie-Salmon, International Staging System (ISS), and revised ISS (R-ISS) staging classifications for multiple myeloma
  • Table 41: Cancer registry databases used as a source of multiple myeloma incidence data, by country
  • Table 42: Forecasting methodology for multiple myeloma incidence, by country, age group, and gender
  • Table 43: The frequency of ultra-high risk characteristics among smoldering multiple myeloma patients
  • Table 44: Data sources for the Revised International Staging System distribution of multiple myeloma
  • Table 45: Data sources for immunoglobulin isotype distribution of multiple myeloma
  • Table 46: Sources of survival data used to estimate multiple myeloma prevalence, by country
  • Table 47: Incident cases of multiple myeloma in the US, Japan, and five major EU markets, by country, 2016-36
  • Table 48: Age- and gender-specific incident cases of multiple myeloma in the US, Japan, and five major EU markets, by country, 2016
  • Table 49: Incident cases of smoldering, high-risk smoldering, and active multiple myeloma in the US, Japan, and five major EU markets, by country, 2016
  • Table 50: Incident cases of active multiple myeloma in the US, Japan, and five major EU markets, by Revised International Staging System and country, 2016
  • Table 51: Incident cases of active multiple myeloma in the US, Japan, and five major EU markets, by immunoglobulin isotype and country, 2016
  • Table 52: Validation of forecast estimates against benchmark estimates
  • Table 53: Key marketed drugs for multiple myeloma
  • Table 54: Darzalex drug profile
  • Table 55: Darzalex pivotal trial data in multiple myeloma
  • Table 56: Darzalex early-phase trial data in multiple myeloma
  • Table 57: Darzalex ongoing late-phase clinical trials in multiple myeloma
  • Table 58: Empliciti drug profile
  • Table 59: Empliciti pivotal trial data in multiple myeloma
  • Table 60: Empliciti ongoing late-phase clinical trials in multiple myeloma
  • Table 61: Farydak drug profile
  • Table 62: Farydak pivotal trial data in multiple myeloma
  • Table 63: Kyprolis drug profile
  • Table 64: Kyprolis pivotal trial data in multiple myeloma
  • Table 65: Kyprolis late-phase trial data in multiple myeloma
  • Table 66: Kyprolis ongoing late-phase clinical trials in multiple myeloma
  • Table 67: Serious adverse events reported from the ENDEAVOR trial
  • Table 68: Ninlaro drug profile
  • Table 69: Ninlaro pivotal trial data in multiple myeloma
  • Table 70: Ninlaro ongoing late-phase clinical trials in multiple myeloma
  • Table 71: Pomalyst drug profile
  • Table 72: Pomalyst pivotal trial data in multiple myeloma
  • Table 73: Pomalyst late-phase trial data in multiple myeloma
  • Table 74: Pomalyst key ongoing clinical trials in multiple myeloma
  • Table 75: Revlimid drug profile
  • Table 76: Revlimid pivotal trial data in multiple myeloma
  • Table 77: Revlimid late-phase trial data in multiple myeloma
  • Table 78: Thalomid drug profile
  • Table 79: Thalomid pivotal trial data in multiple myeloma
  • Table 80: Velcade drug profile
  • Table 81: Velcade pivotal trial data in multiple myeloma
  • Table 82: Velcade late-phase trial data in multiple myeloma
  • Table 83: Marketed multiple myeloma products and approved indications in the US, Japan, and five major EU markets
  • Table 84: Late-stage candidates in development for multiple myeloma
  • Table 85: Levers impacting access to multiple myeloma drugs in the US and five major EU markets
  • Table 86: Clinical trials of multiple myeloma drugs for maintenance therapy
  • Table 87: US pricing of key marketed drugs
  • Table 88: Phase III clinical trial plan of Darzalex in numerous combinations and treatment settings
  • Table 89: Cost-effectiveness of new second-line treatments according to ICER
  • Table 90: Multiple myeloma clinical pathways used by Anthem's Cancer Care Quality Program
  • Table 91: Formulary placement of Darzalex, Empliciti, Farydak, Kyprolis, Ninlaro, Pomalyst, Revlimid, Thalomid, and Velcade in selected commercial formularies
  • Table 92: Formulary placement of Darzalex, Empliciti, Farydak, Kyprolis, Ninlaro, Pomalyst, Revlimid, Thalomid, and Velcade in top five Medicare Part D formularies
  • Table 93: Prior authorization criteria for Darzalex, Empliciti, Farydak, Kyprolis, Ninlaro, Pomalyst, Revlimid, Thalomid, and Velcade in four major health plans
  • Table 94: Patient assistance programs by marketed drug manufacturers
  • Table 95: Head-to-head trials featuring Kyprolis against current standards of care
  • Table 96: Clinical trial data of multiple myeloma drugs in relapsed/refractory patients
  • Table 97: Pricing premiums given to medicines that can demonstrate benefit over comparators
  • Table 98: Pricing of key marketed multiple myeloma drugs in Japan
  • Table 99: Price calculation methodologies for multiple myeloma drugs in Japan launched after 2008
  • Table 100: Pricing of key multiple myeloma drugs in the five major EU markets
  • Table 101: Transparency Committee's ASMR ratings and pricing implications
  • Table 102: Transparency Committee's SMR ratings and pricing implications
  • Table 103: Transparency Committee's assessment of multiple myeloma treatments
  • Table 104: G-BA assessment of key multiple myeloma therapies
  • Table 105: Reimbursement conditions for multiple myeloma treatments in Italy
  • Table 106: Multiple myeloma drugs on regional formularies in Italy
  • Table 107: Spanish Myeloma Group guidelines
  • Table 108: Spanish national and regional health reimbursement decisions for multiple myeloma drugs
  • Table 109: NICE assessments of key multiple myeloma therapies
  • Table 110: SMC decisions on key multiple myeloma therapies
  • Table 111: NICE multiple myeloma pathway
  • Table 112: Multiple myeloma therapies assessed for inclusion on the Cancer Drugs Fund list
  • Table 113: Price sources and calculations, by country
  • Table 114: Exchange rates used for calculating prices
  • Table 115: Pipeline products in development for multiple myeloma
  • Table 116: Velcade drug profile
  • Table 117: Velcade pivotal trial data in multiple myeloma
  • Table 118: Revlimid drug profile
  • Table 119: Revlimid pivotal trial data in multiple myeloma
  • Table 120: Initial FDA approvals granted to multiple myeloma drugs, 2000-date
  • Table 121: Typical Phase III clinical trial design in multiple myeloma
  • Table 122: Late-stage compounds that were recently discontinued for multiple myeloma
  • Table 123: Aplidin drug profile
  • Table 124: Aplidin Phase III trials in multiple myeloma
  • Table 125: Aplidin Phase II data in multiple myeloma
  • Table 126: Keytruda drug profile
  • Table 127: Keytruda Phase III trials in multiple myeloma
  • Table 128: Keytruda early-phase data in multiple myeloma
  • Table 129: Selinexor drug profile
  • Table 130: Selinexor early-phase trials in multiple myeloma
  • Table 131: Selinexor early-phase data in multiple myeloma
Back to Top